Sanna et al. conjugated the urea-based PSMA inhibitor DCL to the microbubble envelope component poly(lactic-co-glycolic acid-polyethylene glycol (PLGA-PEG), thus generating a targeted ultrasound contrast agent to be used for prostate cancer cell binding evaluations in vitro [30]. This evidence concerns the gene FOLH1 and prostate cancer.